Cancer Weekly articles from October 1992

Cancer Weekly archives from October 1992

APC gene mutation crucial in colorectal cancers. (Johns Hopkins/Imperial Cancer Research Fund)
October 5, 1992... Johns Hopkins/Imperial Cancer Research Fund Two reports published in September 1992 shed light on the role of APC gene mutations in the development of both familial and sporadic colon cancers. In a report published in the September...

Approval expected for taxol. (U.S. Food and Drug Administration)
October 5, 1992... U.S. FDA The government may approve commercial sales of the new anticancer agent Taxol by the end of 1992, triggering a doubling of demand for the tree bark needed to make the drug, a congressman says. Representative Ron Wyden,...

More cancer patients to receive taxol. (U.S. National Cancer Institute)
October 5, 1992... U.S. NCI The experimental anticancer drug Taxol will soon become more widely available to women who have ovarian cancer that has progressed in spite of standard treatment, the U.S. National Cancer Institute (NCI) announced. ...

Scientists discuss genetic control of normal embryonic development and cancers. (Bristol-Myers Squibb Symposium on Cancer Research)
October 5, 1992... Bristol-Myers Squibb A tumor suppressor gene that predisposes to a relatively common childhood cancer, and perhaps adult cancers, also has been found to control the early development of the kidneys, testicles and ovaries. The...

ced-9 gene prevents cell suicide. (Bristol-Myers Squibb Symposium on Cancer Research)
October 5, 1992... Bristol-Myers Squibb A new class of genes that control cell death is beginning to play a major role in cancer research. Between the oncogenes that turn on cell growth and the tumor-suppressor genes that turn it off are the "death"...

Scientists identify virus target; discover factor affecting cell growth. (E2F transcription factor) (Bristol-Myers Squibb Symposium on Cancer Research)
October 5, 1992... Bristol-Myers Squibb Researchers recently have discovered that some common viruses can cause cervical and other cancers by binding to a newly discovered protein and interfering with cell growth controls. The research was reported at...

Researchers study abnormal immune response results in leukemia in mice. (University of California, San Francisco)
October 5, 1992... California A theory for how some leukemias arise in humans may receive renewed consideration as a result of a new study on mice, where chronic viral infection caused cells of the mouse immune system to multiply out of control and led to...

Human clinical trials begin for Smart M195 antibody to treat myeloid leukemia. (Protein Design Labs)
October 5, 1992... Protein Design Labs Protein Design Labs (PDL), Mountain View, California, announced September 22, 1992, that the second of the company's humanized antibodies has entered human clinical trials. The Phase I clinical trial of PDL's...

Scientists conclude dioxin worse than thought. (Environmental Defense Fund)
October 5, 1992... Environmental Defense Fund The Environmental Defense Fund (EDF) has asked Environmental Protection Agency (EPA) Administrator William K. Reilly to get on with the job of eliminating dioxin releases into the environment, now that its...

Mutant mice give clues to cancer. (mice missing the Rb gene) (Massachusetts)
October 5, 1992... Massachusetts In a step that enables researchers to probe the underlying causes of human cancers, three research teams announced they had bred mice missing a gene important in a variety of malignancies. In fact, the researchers who...

R.J. Reynolds studied smoking health effects. (North Carolina)
October 5, 1992... North Carolina R.J. Reynolds Tobacco Company once ran a laboratory to learn the health effects of smoking, but shut it down out of fear its results could be used against the company, a newspaper reported September 25, 1992. In the...

Surgeon describes improved breast implant technique. (Dr. Richard Mladick; saline implants) (Virginia)
October 5, 1992... Virginia A plastic surgeon says he's developed a technique for installing saline-filled breast implants to look and feel more natural. Although long available, saline implants lacked the appeal of silicone-gel filled implants...

One in eight U.S. women will get breast cancer. (U.S. National Cancer Institute)
October 5, 1992... U.S. NCI The U.S. National Cancer Institute (NCI) says one in eight American women will get breast cancer. Previously, the institute said one in nine American women would contract breast cancer by age 85. The institute says the old...

Military funds re-allocated for breast cancer research. (U.S. Senate)
October 5, 1992... U.S. Senate The U.S. Senate has agreed to move $200 million out of 1993's military budget and spend $185 million of that money to expand a small Army-funded breast cancer research project. The House previously had approved $25 million...

Childhood cancer treatment improved in last 15 years. (American Cancer Society)
October 5, 1992... American Cancer Society In the last 15 years, the treatment for many types of childhood cancers, especially leukemia, has greatly improved. The research titled "The Late Effects of Therapy for Childhood Cancer," appear in the...

Insecticide manufactured at Ciba-Geigy found linked to cancer. (chlordimeform, Galecron) (St. Gabriel, Louisiana)
October 5, 1992... Louisiana An insecticide, formerly made and packaged at Ciba-Geigy Corporation's Louisiana and Alabama plants, has been linked to bladder cancer, a spokeswoman for the company says. The insecticide, chlordimeform, was manufactured...

Blacks have highest death rate from prostate cancer. (North Carolina)
October 5, 1992... North Carolina Black men in North Carolina have the highest death rate from prostate cancer in the nation - more than double the rate for whites - according to researchers at the Duke Comprehensive Cancer Center, Durham, North Carolina....

Company receives federal grant for studies of potential cancer therapy. (Large Multivalent Immunogen technology) (Lidak Pharmaceuticals)
October 5, 1992... Lidak Pharmaceuticals Lidak Pharmaceuticals, La Jolla, California, announced it has been awarded a Phase II grant from the U.S. National Institutes of Health's (NIH) Small Business Innovation Research (SBIR) program. The $428,000...

Enhanced myelosuppression in a Phase I trial of recombinant human tumor necrosis factor in combination with etoposide. (Research Report)
October 5, 1992... Enhanced Myelosuppression in a Phase I Trial of AUTHORS: M.L. Sherman, D.R. Spriggs, K.A. Arthur and D.W. Kufe. Dana-Farber Cancer Institute, Boston, Massachusetts. According to the authors' abstract of a poster presentation to the...

Pathologic changes in the human gastrointestinal tract secondary to immunotherapy with the monoclonal antibody D612. (Research Report )
October 5, 1992... AUTHORS: W.E. Grizzle, M.N. Saleh, R.H. Wheeler, C.R. Stockard and A.F. LoBuglio. University of Alabama at Birmingham. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American Association...

The nuclear matrix as a target for prostate cancer chemotherapy. (Research Report)
October 5, 1992... AUTHORS: K.J. Pienta and L. Meyer. Prentis Comprehensive Cancer Center, Detroit, Michigan. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American Association for Cancer Research, held May...

Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome encapsulated doxorubicin (LED). (Research Report)
October 5, 1992... AUTHORS: R. Masood, A. Rahman, S.R. Husain, S.Z. Salahuddin and P. Gill. Norris Cancer Center, University of Southern California, Los Angeles, California. According to the authors' abstract of a poster presentation to the 83rd annual...

13C nuclear magnetic resonance (NMR) spectroscopy for the characterization of lipid metabolism in patients with malignant disease. (Research Report)
October 5, 1992... AUTHORS: T. Engan, J. Krane, A.L. Hoe, K.S. Bjerve, M. Vabeno and S. Kvinnsland. Trondheim University Hospital and the Center for Nuclear Magnetic Resonance, Trondheim, Norway. According to the authors' abstract of a poster presentation...

Detection of clonal cell populations using a novel RNA polymerase chain reaction assay. (Research Report)
October 5, 1992... AUTHORS: D. Reardon, V. Terry and M. Roth. University of Michigan Medical School, Ann Arbor, Michigan. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American Association for Cancer...

Genomic imprinting in medulloblastoma: maternal imprinting of a tumor suppressor gene. (Research Report)
October 5, 1992... AUTHORS: E. Mack, L. Daneshvar, J. Tseng and P. Cogen. Brain Tumor Research Center, San Francisco, California. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American Association for Cancer...

Amplification of int-2 gene as a biological prognostic marker in human gastric cancer. (Research Report)
October 5, 1992... AUTHORS: K. Kikuchi, M. Ueda, M. Fujisaki, M. Watanabe, A .Tsuyuki, Y. Fujishiro and T. Ishihara. Keio Cancer Center, Tokyo, Japan. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American...

Radio-chemotherapy simulated in vitro by a new 3-D-computer model of multimodal pharmacodynamic interaction. (Research Report )
October 5, 1992... AUTHORS: U. Bogdahn, A. Jager, B. Pfeufer, J. Richter, A. Justh and R. Apfel. University of Wurzburg, Wurzburg, Germany. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American Association...

Phase II trial of 4'-O-tetrahydropyranyladriamycin (Pirarubicin) in head and neck carcinoma. (Periodical Report)
October 5, 1992... SOURCE: Cancer, September 15, 1992;70(6):1591-1597. Pirarubicin is an active agent in the treatment of head and neck cancer with acceptable toxicity, according to a report from the University of Miami School of Medicine, Miami, Florida....

Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. (Periodical Report)
October 5, 1992... SOURCE: Proceedings of the National Academy of Sciences, September, 1992;89:7973-7977. Tumor immunophotodiagnosis is feasible at the clinical level in the detection of colon cancers, according to a report from a Swiss research...

Treatment of recurrent gliomas with eflornithine. (Periodical Report)
October 5, 1992... SOURCE: Journal of the National Cancer Institute, September 16, 1992;84(18):1432-1437. Eflornithine given alone is an effective palliative therapy for recurrent anaplastic gliomas, according to a report from the M.D. Anderson Cancer...

p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. (Periodical Report)
October 5, 1992... SOURCE: International Journal of Cancer, September, 1992;52:178-182. p53 over-expression appears to be unrelated to the biological aggressiveness of human squamous-cell carcinoma of the larynx, according to an Italian study. The...

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. (Periodical Report)
October 5, 1992... SOURCE: Journal of Clinical Oncology, September, 1992;10(9):1479-1484. The attainment of a surgically-defined complete response after intraperitoneal chemotherapy appears to have an impact on survival in ovarian cancer patients with...

Prognostic significance of the PC10 index as a prospective assay for cervical cancer treated with radiation therapy alone. (Periodical Report)
October 5, 1992... SOURCE: Cancer, September 15, 1992;70(6):1545-1549. The PC10 index may be a predictive indicator for the prognosis of patients with squamous cell carcinoma of the cervix treated with radiation therapy alone, according to a report from...

Fred Hutchinson Cancer Research Center awarded $140 million contract. (for the Women's Health Initiative) (U.S. National Institutes of Health)
October 12, 1992... U.S. NIH The Fred Hutchinson Cancer Research Center, Seattle, Washington, was awarded a contract by the U.S. National Institutes of Health (NIH) to act as the clinical coordinating center for the Women's Health Initiative (WHI), the...

Gene that triggers certain leukemias found. (California)
October 12, 1992... California Scientists say they have found a gene that triggers certain forms of leukemia, a discovery that may lead to development of a screening test and better treatments. The gene is involved in perhaps half the cases of...

Aspirin may reduce risk of fatal colon cancer. (Emory University/American Cancer Society)
October 12, 1992... Emory University/American Cancer Society A large epidemiological study suggests that regular aspirin use may lessen the risk of fatal colon cancer. The study, conducted by researchers at Atlanta's Emory University and the American...

Hoarseness, unexplained voice changes can signal throat cancer. (University of Iowa College of Medicine)
October 12, 1992... Iowa Hoarseness or other unexplained changes in voice quality can be early warning signs of throat cancer, especially for men over 50, researchers at the University of Iowa College of Medicine discovered. In a follow-up study of 73...

Routine ovarian CA-125 testing and ultrasound screening not advised. (Michigan)
October 12, 1992... Michigan Gilda Radner's death did much to raise public awareness of ovarian cancer, but it also left women misinformed about screening tests for this deadly disease, that has an overall survival rate of only 20-25 percent. Radner's...

Lung specimens taken during autopsies show link between passive smoking and cancer. (American Medical Association)
October 12, 1992... American Medical Association Examination of lung samples taken during autopsies shows that passive smoke is a contributing factor to lung cancer, according to a study published in the October 7, 1992, issue of the Journal of the American...

Cigarette contents largely unregulated. (North Carolina)
October 12, 1992... North Carolina The tide is turning against the tobacco industry, which has been damaged by recent disclosures about scientific research into the danger of cigarettes, anti-smoking activists say. U.S. Representative Richard Durbin,...

Health groups want low-tar, low-nicotine cigarettes regulated. (Massachusetts)
October 12, 1992... Massachusetts Charging that low-tar, low-nicotine cigarettes give the tobacco industry an unhealthy marketing tool, three national health organizations asked five states to consider the products drugs and regulate them accordingly. ...

First SPORE grants awarded. (Specialized Programs of Research Excellence) (U.S. National Cancer Institute)
October 12, 1992... U.S. NCI To encourage rapid development of new and innovative cancer research in areas of high priority, the U.S. National Cancer Institute (NCI) announced the first awards for Specialized Programs of Research Excellence (SPORE). ...

Oncogene Science receives grant to develop treatment for leukemia. (U.S. National Cancer Institute)
October 12, 1992... U.S. NCI Oncogene Science Inc. announced that it has been awarded a U.S. National Cancer Institute (NCI) grant to develop novel drugs for the treatment of leukemias involving chromosomal translocation, with primary focus on chronic...

Laboratory to develop new techniques to treat viral infections and cancer. (Collaborative Laboratory of Viral Engineering at the University of Oxford) (England)
October 12, 1992... England British Bio-technology Group plc, Oxford, England, and the University of Oxford announced the establishment of a new Collaborative Laboratory of Viral Engineering within the university which will pursue research into new ways of...

Company announces collaboration on antibody products for cancer therapy. (with Eli Lilly and Co.) (GenPharm International Inc.)
October 12, 1992... GenPharm International GenPharm International Inc., Mountain View, California, announced a collaboration with Eli Lilly and Co. to develop human monoclonal antibodies for use in treating certain cancers. These antibodies will be...

Seragen Inc. announces approval of clinical trials for new IL-2 fusion toxin. (patients with rheumatoid arthritis or certain lymphomas) (U.S. Food and Drug Administration)
October 12, 1992... U.S. FDA Seragen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved two Investigational New Drug (IND) Applications for human clinical trials of [DAB.sub.389]IL-2, a new version of its Interleukin-2 (IL-2)...

Phase III clinical trial begins for recombinant thyroid stimulating hormone. (Minnesota)
October 12, 1992... Minnesota Results from Genzyme Corp.'s Phase I/II clinical study of recombinant human thyroid stimulating hormone (rhTSH) were presented by investigators at the Annual American Thyroid Association Conference in Rochester, Minnesota. ...

Vivigen announces expanded cancer testing menu. (New Mexico)
October 12, 1992... New Mexico Vivigen Inc., Santa Fe, New Mexico, has announced the expansion of the company's cancer diagnostic testing menu from its original cytogenetic base to include a tumor marker program, molecular oncology and flow cytometry (in...

Yew nurseries a future source of taxol. (Weyerhaeuser Co. growing yews for Bristol-Myers Squibb) (Oregon)
October 12, 1992... Oregon By the middle of the decade, yew trees at Weyerhaeuser Co. nurseries are expected to yield a giant share of the cancer-fighting drug Taxol. Weyerhaeuser has planted 5 million yew trees in its two forest nurseries in Aurora,...

State finds thyroid cancer elevated in Los Alamos. (New Mexico)
October 12, 1992... New Mexico Annual rates of thyroid cancer cases in Los Alamos, New Mexico, from 1986 to 1990 were four times higher than the rate for the rest of the state, the state Health Department has reported. The rates of brain cancer cases...

Congress sends Bush bill on DES education, research. (diethylstilbestrol)
October 12, 1992... U.S. Congress The U.S. Senate has approved and sent to President Bush a bill that would expand research and begin an education campaign about DES, the drug once prescribed to pregnant mothers and now linked to cancer. The bill,...

Bill provides reimbursement to cancer patients for prescribed off-label drugs. (California)
October 12, 1992... California California cancer patients who have been denied or delayed insurance reimbursement for proven, safe and effective off-label drugs will now have access to them thanks to a new bill signed by Governor Pete Wilson and authored by...

Primary systemic amyloidosis (AL): a rare complication of IgM monoclonal gammopathies and Waldenstrom's macroglobulinemia. (Research Report)
October 12, 1992... AUTHORS: M.A. Gertz and R.A. Kyle. Mayo Clinic, Rochester, Minnesota. According to the authors' abstract of a poster presentation to a joint meeting of the Central Society for Clinical Research, the Midwest Section of the American...

Immunotherapy of malignancy by in vivo gene transfer into tumors. (Research Report)
October 12, 1992... AUTHORS: Gregory E. Plautz, Zhi-yong Yang, Xiang Gao, Leaf Huang and Gary J. Nabel. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan. According to the authors' abstract of a poster presentation to a joint...

Cisplatin inhibits the production of monocyte-derived interleukin-1 receptor antagonist. (Research Report)
October 12, 1992... AUTHORS: D.A. Arenberg, S.L. Kunkel, T.J. Standiford, M.D. Burdick and R.M. Strieter. The University of Michigan Medical School, Ann Arbor, Michigan. According to the authors' abstract of a poster presentation to a joint meeting of the...

Phorbol ester and novobiocin induce apoptosis in HL-60 promyelocytes but not in the PET-cell phorbol ester tolerant mutant. (Research Report)
October 12, 1992... AUTHORS: Donald E. Macfarlane and Peter S. O'Donnell. Veterans Administration Medical Center and the University of Iowa, Iowa City, Iowa. According to the authors' abstract of a poster presentation to a joint meeting of the Central...

Dose-intensive chemotherapy with hematopoietic growth factors and autologous marrow support for advanced breast cancer: beneficial stimulating factor. (Research Report)
October 12, 1992... AUTHORS: D.A. Stevens, J.P. Lynch, L.S. Sender, P.D. Mangino, R.C. Meagher, C.P. Murphy, E.A. Harden, G.H. Goldsmith and R.H. Herzig. University of Louisville, Louisville, Kentucky. According to the authors' abstract of a poster...

Phase I study of 2-chlorodeoxyadenosine in hematologic malignancies. (Research Report)
October 12, 1992... AUTHORS: R.T. Spielberger, S. O'Brien, M.J. Ratain and R.A. Larson. University of Chicago, Chicago, Illinois. According to the authors' abstract of a poster presentation to the 32nd Interscience Conference on Antimicrobial Agents and...

A Phase I cohort of suramin in patients with advanced cancer. (Research Report)
October 12, 1992... AUTHORS: K. Kobayashi, E.E. Vokes, L. Janisch, F. Berezin, N.J. Vogelzang and M.J. Ratain. University of Chicago Section of Hematology/Oncology, Chicago, Illinois. According to the authors' abstract of a poster presentation to the 32nd...

Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. (Periodical Report)
October 12, 1992... SOURCE: Cancer, September 15, 1992;70(6):1625-1633. Infants older than six months of age who have stage IV neuroblastoma require aggressive therapy, according to a report from an Italian research group. Infants with neuroblastoma...

Clinical correlates of MDR1 P-glycoprotein gene expression in ovarian and small-cell lung carcinomas. (Periodical Report)
October 12, 1992... SOURCE: Journal of the National Cancer Institute, October 7, 1992;84(19):1486-1491. The MDR1 gene appears to be expressed in a subpopulation of more malignant tumor cells possessing multiple mechanisms of drug resistance, suggesting...

Outcome of renal transplantation or dialysis in patients with a history of renal cancer. (Periodical Report)
October 12, 1992... SOURCE: Cancer, September 15, 1992;70(6):1564-1567. Renal cancer patients who have had bilateral nephrectomy or removal of a solitary kidney should wait at least one year before proceeding with kidney transplantation, according to a...

Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. (Periodical Report)
October 12, 1992... SOURCE: Annals of Internal Medicine, September 15, 1992;117(6):466-469. The administration of fludarabine plus prednisone is associated with an increased incidence of listeriosis in patients with chronic lymphocytic leukemia, according...

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. (Periodical Report)
October 12, 1992... SOURCE: Journal of the National Cancer Institute, October 7, 1992;84(19):1512-1517. ERCC1 expression levels in human tumor tissue may have a role in clinical resistance to platinum compounds, adding to the evidence that ERCC1 serves as...

Study shows RU-486 can control brain cancer. (University of Southern California)
October 19, 1992... University of Southern California Results of a study indicating the so-called abortion pill can control a certain type of brain cancer has led to a comprehensive survey of 200 patients now underway. Steven Grunberg, an oncologist at...

Study suggests brain tumors suppress immune response. (University of California, Los Angeles School of Medicine)
October 19, 1992... California Immunotherapy, showing promise as a major form of cancer treatment, may not work effectively, as it is presently known, against tumors of the brain, according to researchers at the University of California, Los Angeles (UCLA)...

Doctors look to immune system in fight against pediatric neuroblastoma. (St. Jude Children's Research Hospital, Tennessee)
October 19, 1992... Tennessee Investigators at St. Jude Children's Research Hospital, Memphis, Tennessee, are looking at ways to strengthen the immune systems of young cancer patients by using gene therapy. A new study will concentrate on children with...

Researchers search for breast cancer clues. (State University of New York, Stony Brook)
October 19, 1992... State University of New York, Stony Brook State University of New York, (SUNY) at Stony Brook, Health Sciences Center researchers are studying diagnostic markers for breast cancer to determine why some women with early breast cancer...

Scientists studying estrogen receptors in breast cancer. (State University of New York, Stony Brook)
October 19, 1992... State University of New York, Stony Brook State University of New York, at Stony Brook, Health Sciences Center researcher is studying how "outlaw" estrogen receptors may play a role in the development of breast cancer. Richard...

Clinical trial of Ceprate SC Stem Cell concentration system announced. (Emory University Hospital)
October 19, 1992... Emory University Hospital CellPro Inc., Bothell, Washington, reported that research physicians at Emory University Hospital, Atlanta, Georgia, are using its Ceprate SC Stem Cell Concentration System to evaluate a new type of bone-marrow...

Breast augmentation may limit effectiveness of mammography. (American Medical Association)
October 19, 1992... American Medical Association Breast implants often make it harder to obtain accurate mammograms, according to a study published in the October 14, 1992 issue of the Journal of the American Medical Association. "In most women with...

Project tests thousands for breast, cervical cancer. (National Breast and Cervical Cancer Early Detection Program) (U.S. Centers for Disease Control)
October 19, 1992... U.S. CDC Thousands of low-income women have received publicly funded mammograms and Pap smears in the first year of the U.S. Centers for Disease Control's (CDC) massive cancer screening project. The $50 million National Breast and...

Breast cancer relatives at increased risk of prostate cancer. (Iceland)
October 19, 1992... Iceland Close relatives of women with breast cancer have a 40 percent greater chance of getting prostate cancer, according to a study of nearly 30,000 people in Iceland. The finding suggests a genetic basis for prostate cancer,...

Company introduces drug to fight childhood leukemia. (Vumon) (Bristol-Myers Squibb)
October 19, 1992... Bristol-Myers Squibb Bristol-Myers Squibb Company has introduced a drug to battle childhood leukemia, the most common form of childhood cancer diagnosed in the U.S. Officials of the company's pharmaceutical division, based in...

Company receives regulatory approval for first human gene therapy trial to treat lung cancer. (Genetic Therapy Inc.)
October 19, 1992... Genetic Therapy Genetic Therapy Inc., Gaithersburg, Maryland, announced that the Recombinant DNA Advisory Committee (RAC) of the U.S. National Institutes of Health (NIH) has approved a human gene therapy trial for the direct in vivo...

Surgery can save lives of some prostate cancer patients. (Mayo Clinic)
October 19, 1992... Mayo Clinic Prostate surgery and surgical or chemical castration can save the lives of many men whose prostate cancer has spread to nearby lymph nodes, Mayo Clinic researchers say. Dr. Horst Zincke, the urologist who headed the...

Much more radiation released in 1940s than first thought. (from plutonium production at Hanford, Washington) (U.S. Centers for Disease Control)
October 19, 1992... U.S. CDC Seventy percent more radiation was released at the Hanford nuclear reservation from 1944 to 1947 than was previously thought, a new study indicates. About 685,000 curies of radioactive iodine 131 were released during the...

Papillomavirus in vitro cell culture systems. (National Institute of Allergy and Infectious Diseases research grant announcement) (Research Report)
October 19, 1992... AUTHORS: RFA Available: AI-92-08. National Institute of Allergy and Infectious Diseases. "Letter of Intent Receipt Date: November 6, 1992. Application Receipt Date: December 10, 1992. Purpose: The Antiviral Research Branch of the...

Clinical trials of cancer therapy with biological response modifiers. (National Cancer Institute research grant announcement) (Research Report)
October 19, 1992... Papillomavirus In Vitro Cell Culture Systems AUTHORS: RFA Available: CA-92-28. National Cancer Institute. "Letter of Intent Receipt Date: October 30, 1992. Application Receipt Date: December 22, 1992. Purpose: The Biological...

Lack of mother-to-child transmission of HTLV-II in non-breast-fed infants. (Research Report)
October 19, 1992... AUTHORS: J. Kaplan, N. Shaffer, R. Van Dyke, E. Abrams, H. Pollack, M. Perrin, B. Roberts, W. Heneine and the NYC Perinatal HIV Transmission Collaborative Study. Centers for Disease Control, Atlanta, Georgia; New York City Department of...

A simple enzyme immunoassay for the discrimination between infection with HTLV-I and HTLV-II. (Research Report)
October 19, 1992... AUTHORS: R.B. Van Dyke, E. Starszak and J.E. Robinson. Tulane and Louisiana State University Schools of Medicine, New Orleans, Louisiana. According to the authors' abstract of a poster presentation to the 32nd Interscience Conference...

Incidence of cytomegalovirus (CMV) pneumonia in adult non-transplant cancer patients: review of 9549 autopsies from 1964-1990. (Research Report)
October 19, 1992... AUTHORS: J.R. Mera, E. Whimbey, M. Luna, A. Preti, L. Elting, S. Vartivarian and T.W. Williams Jr. Baylor College of Medicine and M.D. Anderson Cancer Center (MDACC), Houston, Texas. According to the authors' abstract of a poster...

Influenza A infection in adult leukemia patients. (Research Report)
October 19, 1992... AUTHORS: L. Elting, E. Whimbey, R. Couch, W. Lo, M. Andreeff, O. Falcao and G. Bodey. The Baylor College of Medicine, Houston, Texas. According to the authors' abstract of a poster presentation to the 32nd Interscience Conference on...

Multiple dose pharmacokinetics of a new cyclodextrin solution formulation of itraconazole, (ITR), in patients undergoing remission induction chemotherapy for acute myeloid leukemia. (Research Report)
October 19, 1992... AUTHORS: A.G. Prentice, D.W. Warnock, S.A.N. Johnson and D.A. Oliver. Plymouth Royal Infirmary, Bristol, England, and Musgrove Park Hospital, Taunton, England. According to the authors' abstract of a poster presentation to the 32nd...